Screener
Moderna MRNA Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Moderna’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001682852-26-000060
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Royalties(1) | $967 | $31 |
| Provisions related to product sales (Note 3) | 470 | 509 |
| Compensation-related | 108 | 420 |
| Other external goods and services | 82 | 57 |
| Development operations | 81 | 106 |
| Manufacturing | 79 | 140 |
| Clinical trials | 46 | 20 |
| Property, plant and equipment | 31 | 45 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Moderna's accrued manufacturing costs?
- Moderna (MRNA) reported accrued manufacturing costs of $108M in Q1 2026.
- How has Moderna's accrued manufacturing costs changed year-over-year?
- Moderna's accrued manufacturing costs decreased by 10.0% year-over-year, from $120M to $108M.
- What is the long-term trend for Moderna's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Moderna's accrued manufacturing costs has grown at a 34.6% compound annual growth rate (CAGR), from $95M to $420M.
Ask your AI about Moderna's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude